Thoratec Says Thrombosis Fears Are Immaterial So Far, But Remains Vigilant
This article was originally published in The Gray Sheet
Executive Summary
Thoratec says that the recent article in the New England Journal of Medicine describing surprisingly high rates of pump thrombosis in left-ventricular assist devices may have short-term sales implications, but they will minimize over time. The company says it is working with clinical centers on best practices to avoid thrombosis.